Targeting Iron Deficiency Anemia in Heart Failure.
Study Goal
The researchers aimed to evaluate the effects of intravenous iron supplementation on functional capacity and quality of life in iron-deficient heart failure patients.
Results Summary
Intravenous iron supplementation improved short-term functional capacity and quality of life in iron-deficient HF patients, with benefits sometimes independent of hemoglobin levels. Long-term safety and mechanisms of benefit require further investigation.
Population
Iron-deficient heart failure patients
Effective Dosage
Not specified
Duration
Short-term (specific duration not mentioned)
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
intravenous iron supplementation | increase | functional capacity | iron-deficient HF patients | - | demonstrated short-term improvement | #1 |
intravenous iron supplementation | increase | quality of life | iron-deficient HF patients | - | demonstrated short-term improvement | #2 |
iron supplementation | no change | hemoglobin levels | - | - | benefits were independent | #3 |
Iron deficiency is common in heart failure (HF) patients, and is associated with increased risk of adverse clinical outcomes. Clinical trials of intravenous iron supplementation in iron-deficient HF patients have demonstrated short-term improvement in functional capacity and quality of life. In some trials, the benefits of iron supplementation were independent of the hemoglobin levels. Additional investigations of iron supplementation are needed to characterize the mechanisms contributing to clinical benefit and long-term safety in HF.